{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:03:25Z","timestamp":1770825805640,"version":"3.50.1"},"reference-count":50,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T00:00:00Z","timestamp":1584403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/50006\/2020"],"award-info":[{"award-number":["UIDB\/50006\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>The present review presents an overview of antitumor pyrazoles of natural or bioinspired origins. Pyrazole compounds are relatively rare in nature, the first ones having been reported in 1966 and being essentially used as somniferous drugs. Cytotoxic pyrazoles of natural sources were first isolated in 1969, and a few others have been reported since then, most of them in the last decade. This paper presents a perspective on the current knowledge on antitumor natural pyrazoles, organized into two sections. The first focuses on the three known families of cytotoxic pyrazoles that were directly isolated from plants, for which the knowledge of the medicinal properties is in its infancy. The second section describes pyrazole derivatives of natural products, discussing their structure\u2013activity relationships.<\/jats:p>","DOI":"10.3390\/molecules25061364","type":"journal-article","created":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T07:29:07Z","timestamp":1584689347000},"page":"1364","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Natural and Biomimetic Antitumor Pyrazoles, A Perspective"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4560-6172","authenticated-orcid":false,"given":"N\u00e1dia E.","family":"Santos","sequence":"first","affiliation":[{"name":"LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8983-9202","authenticated-orcid":false,"given":"Ana R.F.","family":"Carreira","sequence":"additional","affiliation":[{"name":"CICECO\u2013Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0938-5085","authenticated-orcid":false,"given":"Vera L. M.","family":"Silva","sequence":"additional","affiliation":[{"name":"LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4460-970X","authenticated-orcid":false,"given":"Susana Santos","family":"Braga","sequence":"additional","affiliation":[{"name":"LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2020,3,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0944-7113(97)80081-5","article-title":"Paclitaxel (Taxol\u00ae): A new natural product with major anticancer activity","volume":"4","year":"1997","journal-title":"Phytomed"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"482","DOI":"10.6061\/clinics\/2018\/e482s","article-title":"Marine drugs for cancer: Surfacing biotechnological innovations from the oceans","volume":"73","author":"Jimenez","year":"2018","journal-title":"Clinics (Sao Paulo)"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.chembiol.2011.12.014","article-title":"Lessons from the past and charting the future of marine natural products drug discovery and chemical biology","volume":"19","author":"Gerwick","year":"2012","journal-title":"Chem. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.4155\/fmc.11.118","article-title":"Marine natural products: A new wave of drugs?","volume":"3","author":"Montaser","year":"2011","journal-title":"Future Med. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.biotechadv.2011.03.001","article-title":"Bio-mining the microbial treasures of the ocean: New natural products","volume":"29","author":"Imhoff","year":"2011","journal-title":"Biotechnol. Adv."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s12325-016-0344-3","article-title":"Trabectedin for soft tissue sarcoma: Current status and future perspectives","volume":"33","author":"Gordon","year":"2016","journal-title":"Adv. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1023\/A:1006898812618","article-title":"The anti-cancer agent distamycin A displaces essential transcription factors and selectively inhibits myogenic differentiation","volume":"169","author":"Taylor","year":"1997","journal-title":"Mol. Cell Biochem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bmc.2006.07.004","article-title":"Hybrid molecules between distamycin A and active moieties of antitumor agents","volume":"15","author":"Baraldi","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4989","DOI":"10.1021\/jo020058r","article-title":"Leucamide A: A New Cytotoxic Heptapeptide from the Australian Sponge Leucetta microraphis","volume":"67","author":"Kehraus","year":"2002","journal-title":"J. Org. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1016\/S0960-894X(97)10104-4","article-title":"(-)-Phenylahistin: A new mammalian cell cycle inhibitor produced by Aspergillus ustus","volume":"22","author":"Kanoh","year":"1997","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1271\/bbb.63.1130","article-title":"Antitumor Activity of Phenylahistin in Vitro and in Vivo","volume":"63","author":"Kanoh","year":"1999","journal-title":"Biosci. Biotech. Biochem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/0006-2952(91)90031-Y","article-title":"Antitumor activity and biochemical effects of topsentin","volume":"42","author":"Burres","year":"1991","journal-title":"Biochem. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ejmech.2013.08.053","article-title":"Pyrazole containing natural products: Synthetic preview and biological significance","volume":"69","author":"Kumar","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1016\/S0040-4020(01)99082-9","article-title":"Withasomnine. A pyrazole alkaloid from Withania somnifera Dun","volume":"22","author":"Neumann","year":"1966","journal-title":"Tetrahedron"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1055\/s-2006-957380","article-title":"New Pyrazole Alkaloids from the Root Bark of Newbouldia laevis","volume":"64","author":"Aladesanmi","year":"1998","journal-title":"Planta Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0305-1978(00)00109-5","article-title":"Pyrazole alkaloids from Elytraria acaulis","volume":"29","author":"Ravikant","year":"2001","journal-title":"Biochem. System. Ecol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Mokhlesi, A., Hartmann, R., Kurt\u00e1n, T., Weber, H., Lin, W., Chaidir, C., M\u00fcller, W.E.G., Daletos, G., and Proksch, P. (2017). New 2-Methoxy Acetylenic Acids and Pyrazole Alkaloids from the Marine Sponge Cinachyrella sp.. Mar. Drugs, 15.","DOI":"10.3390\/md15110356"},{"key":"ref_18","first-page":"380","article-title":"Potentiating Effect of 1, 2-diazole a plant alkaloid on carrageenan and formalin induced paw edema in experimental mice","volume":"4","author":"Prabhu","year":"2012","journal-title":"Int. J. Pharm. Pharm. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/S1734-1140(13)71079-X","article-title":"1,2-Diazole prevents cisplatin-induced nephrotoxicity in experimental rats","volume":"65","author":"Prabhu","year":"2013","journal-title":"Pharmacol. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.gene.2018.09.014","article-title":"Targeting apoptosis by 1,2-diazole through regulation of EGFR, Bcl-2 and CDK-2 mediated signaling pathway in human nonsmall cell lung carcinoma A549 cells","volume":"679","author":"Prabhu","year":"2018","journal-title":"Gene"},{"key":"ref_21","unstructured":"(2020, February 07). FDA Approves Encorafenib and Binimetinib in Combination for Unresectable or Metastatic Melanoma with BRAF Mutations, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-encorafenib-and-binimetinib-combination-unresectable-or-metastatic-melanoma-braf."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"441","DOI":"10.21873\/invivo.11793","article-title":"Eruptive melanocytic nevi secondary to Encorafenib for BRAF mutant metastatic colorectal cancer","volume":"34","author":"Meneguzzo","year":"2020","journal-title":"In Vivo"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11010-019-03554-3","article-title":"Encorafenib inhibits migration, induces cell cycle arrest and apoptosis in colorectal cancer cells","volume":"459","author":"Li","year":"2019","journal-title":"Mol. Cell. Biochem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"30453","DOI":"10.18632\/oncotarget.8351","article-title":"Comparative profiles of BRAF inhibitors: The paradox index as a predictor of clinical toxicity","volume":"7","author":"Adelmann","year":"2016","journal-title":"Oncotarget"},{"key":"ref_25","unstructured":"(2020, February 12). FDA Approves Crizotinib Capsules, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-crizotinib-capsules."},{"key":"ref_26","first-page":"309","article-title":"Long-term complete response in a patient with postoperative recurrent ALK-rearranged lung adenocarcinoma treated with crizotinib: A case report","volume":"11","author":"Kosaka","year":"2019","journal-title":"Mol. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4103\/2278-330X.110506","article-title":"Crizotinib: A comprehensive review","volume":"2","author":"Sahu","year":"2013","journal-title":"South Asian J. Cancer."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.phytol.2015.02.017","article-title":"Pyrazole alkaloids from watermelon (Citrullus lanatus) seeds","volume":"12","author":"Kikuchi","year":"2015","journal-title":"Phytochem. Lett."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Zhao, G., Yao, S., Rothchild, K.W., Liu, T., Liu, Y., Lian, J., He, H.-Y., Ryan, K.S., and Du, Y.-L. (2020). The biosynthetic gene cluster of pyrazomycin\u2014A C-nucleoside antibiotic with a rare pyrazole moiety. ChemBioChem.","DOI":"10.1101\/707406"},{"key":"ref_30","unstructured":"Williams, R., and Hoehn, M. (1974). Pyrazomycin and Process for Production Thereof. (US3802999A), Patent."},{"key":"ref_31","first-page":"2869","article-title":"Phase and cell cycle specificity of pyrazofurin action","volume":"40","author":"Olah","year":"1980","journal-title":"Cancer Res."},{"key":"ref_32","first-page":"2619","article-title":"Experimental Antitumor Activity of Pyrazomycin","volume":"33","author":"Sweeney","year":"1973","journal-title":"Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1002\/1097-0142(197712)40:6<2806::AID-CNCR2820400609>3.0.CO;2-C","article-title":"A phase I study of pyrazofurin","volume":"40","author":"Salem","year":"1977","journal-title":"Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1021\/acs.jmedchem.5b01157","article-title":"C-Nucleosides to be revisited","volume":"59","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_35","unstructured":"Elevitch, C.R. (2006). Rhizophora apiculata, R. mucronata, R. stylosa, R. \u00d7 annamalai, R. \u00d7 lamarckii (Indo\u2013West Pacific stilt mangrove). Traditional Trees of Pacific Islands: The Culture, Environment and Use, Permanent Agriculture Resources."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3109\/1547691X.2012.660997","article-title":"Anti-inflammatory and anti-tumor activity of the marine mangrove Rhizophora apiculata","volume":"9","author":"Prabhu","year":"2012","journal-title":"J. Immunotox."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ejmech.2018.12.016","article-title":"The therapeutic potential of curcumin: A review of clinical trials","volume":"163","author":"Salehi","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_38","first-page":"1","article-title":"Telomerase: A target for therapeutic effects of curcumin and a curcumin derivative in a \u03b21-42 insult in vitro","volume":"9","author":"Xiao","year":"2014","journal-title":"PLoS ONE"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11010-009-0025-5","article-title":"Molecular mechanism of curcumin induced cytotoxicity in human cervical carcinoma cells","volume":"325","author":"Singh","year":"2009","journal-title":"Mol. Cell Biochem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1021\/jm00106a006","article-title":"Styrylpyrazoles, styrylisoxazoles, and styrylisothiazoles. Novel 5-lipooxygenase and cyclooxygenase inhibitors","volume":"34","author":"Flynn","year":"1991","journal-title":"J. Med. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/ardp.201600067","article-title":"Effects of curcuminoid pyrazoles on cancer cells and on the expression of telomerase related genes","volume":"349","author":"Falomir","year":"2016","journal-title":"Arch. Pharm. Chem. Life Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s13659-017-0143-9","article-title":"Synthesis and Cytotoxic Activity of Novel Tetrahydrocurcumin Derivatives Bearing Pyrazole Moiety","volume":"7","author":"Mahal","year":"2017","journal-title":"Nat. Prod. Bioprospect."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1021\/jm0108404","article-title":"Design, synthesis, DNA binding, and biological evaluation of water-soluble hybrid molecules containing two pyrazole analogues of the alkylating cyclopropylpyrroloindole (CPI) subunit of the antitumor agent CC-1065 and polypyrrole minor groove binders","volume":"44","author":"Baraldi","year":"2001","journal-title":"J. Med. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1021\/jm031104y","article-title":"Design, synthesis, and biological evaluation of hybrid molecules containing \u03b1-methylene-\u03b3-butyrolactones and polypyrrole minor groove binders","volume":"47","author":"Baraldi","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_45","first-page":"114","article-title":"Biotransformation of phthalazine by Fusarium moniliforme and Cunninghamella elegans","volume":"91","author":"Sutherland","year":"1999","journal-title":"Mycologia"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.fitote.2019.04.011","article-title":"A new phthalazinone derivative and a new isoflavonoid glycoside from lichen-associated Amycolatopsis sp.","volume":"135","author":"Zheng","year":"2019","journal-title":"Fitoterapia"},{"key":"ref_47","unstructured":"Menear, K.A., Hummersone, M.G., Gomez, S., Javaid, M.H., and Martin, N.M.B. (2008). Phthalazinone Derivatives and Their Use as Medicament to Treat Cancer. (WO2008122810A1), Patent."},{"key":"ref_48","unstructured":"Boyd, E., Brookfield, F., Courtney, S., Georges, G., Goller, B., Limberg, A., Prime, M., Rueger, P., and Rueth, M. (2007). Phthalazinone Pyrazole Derivatives, Their Manufacture and Use as Pharmaceutical Agents. (WO2007107298A1), Patent."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1021\/jm101346r","article-title":"Phthalazinone Pyrazoles as Potent, Selective, and Orally Bioavailable Inhibitors of Aurora-A Kinase","volume":"54","author":"Prime","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1016\/j.bmcl.2008.07.002","article-title":"Potent and selective pyrazole-based inhibitors of B-Raf kinase","volume":"18","author":"Hansen","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/6\/1364\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:07:31Z","timestamp":1760173651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/6\/1364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,17]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["molecules25061364"],"URL":"https:\/\/doi.org\/10.3390\/molecules25061364","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,17]]}}}